Education
About Us
Working with TipRanks
Follow Us
Akero Therapeutics (AKRO)
:AKRO
Total Valuation
Akero Therapeutics has a market cap or net worth of ―. The enterprise value is $3.16B.
Market Cap―
Enterprise Value$3.16B
Share Statistics
Akero Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Akero Therapeutics’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -36.29%.
Return on Equity (ROE)-0.34
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-36.29%
Return on Capital Employed (ROCE)-0.36
Revenue Per Employee―
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Akero Therapeutics is ―. Akero Therapeutics’s PEG ratio is -0.25.
PE Ratio―
PS Ratio0.00
PB Ratio2.49
Price to Fair Value2.49
Price to FCF-8.12
Price to Operating Cash Flow-17.51
PEG Ratio-0.25
Income Statement
In the last 12 months, Akero Therapeutics had revenue of 0.00 and earned -252.06M in profits. Earnings per share was -3.75.
Revenue0.00
Gross Profit0.00
Operating Income-285.42M
Pretax Income-252.06M
Net Income-252.06M
EBITDA-247.37M
Earnings Per Share (EPS)-3.75
Cash Flow
In the last 12 months, operating cash flow was -250.17M and capital expenditures 0.00, giving a free cash flow of -250.17M billion.
Operating Cash Flow-250.17M
Free Cash Flow-250.17M
Free Cash Flow per Share-10.00T>
Dividends & Yields
Akero Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change91.35%
50-Day Moving Average53.87
200-Day Moving Average48.37
Relative Strength Index (RSI)69.15
Average Volume (3m)―
Important Dates
Akero Therapeutics upcoming earnings date is Mar 12, 2026, Before Open (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 12, 2026
Ex-Dividend Date―
Financial Position
Akero Therapeutics as a current ratio of 19.38, with Debt / Equity ratio of 3.63%
Current Ratio19.38
Quick Ratio19.38
Debt to Market Cap0.02
Net Debt to EBITDA1.07
Interest Coverage Ratio-61.14
Taxes
In the past 12 months, Akero Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Akero Therapeutics EV to EBITDA ratio is -5.48, with an EV/FCF ratio of -6.80.
EV to Sales0.00
EV to EBITDA-5.48
EV to Free Cash Flow-6.80
EV to Operating Cash Flow-6.80
Balance Sheet
Akero Therapeutics has $737.83M in cash and marketable securities with $1.16M in debt, giving a net cash position of $736.66M billion.
Cash & Marketable Securities$737.83M
Total Debt$1.16M
Net Cash$736.66M
Net Cash Per Share$10.00T>
Tangible Book Value Per Share$11.17
Margins
Gross margin is 25.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin25.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Akero Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-0.06%